linjc16/ctgov huggingface dataset:
Monotherapy Versus Placebo Over 10 Days in Integrase Naive HIV-1 Infected Adults

Study Overview
=================
Brief Summary
-----------------
To investigate safety, tolerability and anti-viral activity in Integrase-Naïve HIV-1 infected adults

Official Title
-----------------
A Phase 2a, Multicenter, Randomized, Parallel, Double-Blind, Dose Ranging, Placebo-Controlled Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK364735 Monotherapy Versus Placebo Over 10 Days in HIV-1 Infected Adults.

Conditions
-----------------
Infection, Human Immunodeficiency Virus, HIV-1 Infection

Intervention / Treatment
-----------------
* Drug: GSK364735


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Documented HIV-1 infection with screening viral load between 5000 and 300,000 copies/mL. Baseline CD4 cell count greater than 100. Females must be of non-childbearing potential Not have received antiretroviral therapy in the 12 weeks prior to first dose. Exclusion criteria: Must not be infected with hepatitis B or C. Patients must not have any acute laboratory abnormality. Must not have any active CDC (Centers for Disease Control and Prevention)Category C disease (1993), except cutaneous Kaposi's sarcoma not requiring systemic therapy during the trial.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: GSK364735|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in viral load |  | from Day 1 to Day 11 | 
| Amount of drug in blood |  | on Days 1 and 10. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Immunologic effect Development of resistance mutations Viral load change and drug levels in semen for a group of patients |  | throughout the study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
GSK364735, HIV-1, integrase inhibitor
Ovarian Cancer Hemoscope Trial

Study Overview
=================
Brief Summary
-----------------
This is a prospective, gold standard observational trial designed to enroll consecutive, consenting ovarian cancer patients for the purpose of determining sensitivity of an assay that detects circulating tumor DNA. This observational pilot trial will also be used to examine the genetic variants/mutations present in the tumor tissue DNA.

Conditions
-----------------
Ovarian Neoplasms

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Case Group Patients with ovarian cancer undergoing surgery (all stages) Over 18 years old Control Group Patients with a benign gynecological condition undergoing surgery Over 18 years old Exclusion Criteria: Previous cancer diagnosis (all) Radiation therapy before surgical treatment Bone marrow transplant Chemotherapy before surgical treatment Invasive procedure resulting in damage to tissue (e.g., surgery, biopsy, thermal ablation) in the 7 days prior to baseline (pre-surgical) blood collection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Ovarian Cancer<br> | |
| Benign Neoplasm<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sensitivity of an assay that detects circulating tumor DNA |  | 3 years |
Obstructive Sleep Apnea, Retinal Vein Occlusion, Retinal Artery Occlusion

Study Overview
=================
Brief Summary
-----------------
Obstructive sleep apnea is a common disorder linked to serious long-term adverse health consequences; such as hypertension, metabolic dysfunction, cardiovascular disease. Retinal vascular occlusion is related to many systemic illnesses especially hypertension. Obstructive sleep apnea is also related to vascular endothelial dysfunction and vascular endothelial growth factor elevation which causes vision threatening complications of retinal vascular occlusion. Therefore the relationship between obstructive sleep apnea and retinal vascular occlusion should be studied.

Official Title
-----------------
Obstructive Sleep Apnea, Retinal Vein Occlusion, Retinal Artery Occlusion

Conditions
-----------------
Retinal Vascular Occlusion

Intervention / Treatment
-----------------
* Device: Watchpat 100


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any patient who visits outpatient clinic and diagnosed as retinal vascular occlusion which occurred within recent 3 months Exclusion Criteria: Any ocular disease other than retinal vascular occlusion (for example: floppy eyelid syndrome, uveitis, glaucoma, other retinal diseases) Patient who has difficulty answering the questionnaires or portable sleep monitoring Patient who refuses the study enroll

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Watchpat 100|Watchpat 100 is a noninvasive portable sleep monitoring device which monitors peripheral arterial tone, pulse, oxygen saturation, snoring, and body position. Patient places one probe at his or her finger and another sensor at front of the chest and Watchpat 100 monitors the patient overnight.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Watchpat-100(noninvasive portable sleep monitoring device) | Result Data of Watchpat-100 : apnea-hypopnea index(AHI) | after finishing the tests with Watchpat-100 | 
| Berlin questionnaire | Incidence of patients at risk for obstructive sleep apnea according to the Berlin questionnaire | after finishing the Berlin questionnaire | 
| Epworth sleepiness scale | Incidence of patients with daytime sleepiness according to the Epworth sleepiness scale. | after finishing the Epworth sleepiness sclae |
Percutaneous Fixation of Acute Scaphoid Fractures

Study Overview
=================
Brief Summary
-----------------
Percutaneous Trans-trapezial fixation of acute Scaphoid fractures by Herbert screw

Detailed Description
-----------------
Aim of the work: To assessment outcomes of percutaneous Trans-trapezial fixation of acute scaphoid fracture. Operative Technique: Anesthesia: carried out under general anesthesia or brachial plexus block and under tourniquet control. Position: supine. Approach: Percutaneous Trans-trapezial fixation of acute Scaphoid fracture. Recording any intraoperative complication that may affect the result. Postoperative Follow Up: Short arm circular cast including the thumb will be applied. After 3 weeks, cast will be removed and exercises will start.

Official Title
-----------------
Percutaneous Trans-trapezial Fixation of Acute Scaphoid Fractures by Herbert Screw

Conditions
-----------------
Scaphoid Fracture

Intervention / Treatment
-----------------
* Procedure: Percutaneous fixation of acute Scaphoid fractures


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Acute stable non displaced waist fracture (A2). Acute unstable oblique distal third (B1). Acute unstable displaced waist (B2). Acute un stable fracture dislocation (B4). Acute un stable comminuted fracture (B5). Exclusion Criteria: - Acute stable fracture tubercle (A1). Acute unstable fracture proximal pole (B3). Delayed union fracture (C). Established non-union fracture includes fibrous (D1) and sclerotic (D2). Bilateral fractures because of possible interference with postoperative grip strength measurement.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: group (1)<br>group (1) who are complaining of acute scaphoid fractures,we will do percutaneous trans trapezial fixation of scaphoid by Herbert screw.Short arm circular cast including the thumb will be applied. After 3 weeks, cast will be removed and exercises will start. | Procedure: Percutaneous fixation of acute Scaphoid fractures<br>* Percutaneous Trans-trapezial fixation of acute Scaphoid fractures by Herbert screw<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of wrist power | Modified Mayo wrist score | Up to 18 months |
Anti-recurrence Treatment of Postresection on HCC Patients With MVI Presence and Over-expression of ASPH

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to explore the effect of Transarterial Chemoembolization (TACE) on the prognosis of patients with microvascular invasion presence(MVI) and overexpression of Aspartate-β-hydroxylase(ASPH).

Official Title
-----------------
Anti-recurrence Treatment of Postresection on Hepatocellular Carcinoma Patients With Microvascular Invasion Presence and Over-expression of Aspartate Beta-hydroxylase: A Randomized Controlled Study

Conditions
-----------------
Hepatocellular Carcinoma

Intervention / Treatment
-----------------
* Procedure: TACE


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Via clinical diagnosis and confirm it is primary liver cancer Pathological evidence of HCC Confirm presence of MVI and over-expression of ASPH after opreation Within Milan criteria Estimate tumor can gain treatment of curing operation No evidence for extrahepatic metestasis liver function ：Child-Pugh A/B Exclusion Criteria: Reject to attend Impossible to come to our hospital for physical examination regularly Patients with apparent cardiac, pulmonary, cerebral and renal dysfunction Female with pregnancy or during the lactation period

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Group TACE<br>Patients will treated with TACE after resection. | Procedure: TACE<br>* Patients will treated by TACE in 4 or 8 weeks after operation.<br>* Other names: Transhepatic Arterial Chemotherapy And Embolization;|
| No Intervention: Group Control<br>Patients will treated without TACE after resection. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall Survival |  | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to recurrence |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Recurrence, Microvascular Invasion, Aspartate beta-hydroxylase
A Randomized Study to Evaluate a Novel Method of Specific Allergen Immunotherapy

Study Overview
=================
Brief Summary
-----------------
Allergen specific immunotherapy (SIT) is the only causative treatment of IgE-mediated allergies. The disadvantages of SIT, however, are the requirement of numerous allergen administrations over three to five years, and that the treatment itself causes frequent allergic reactions. We aim at enhancing grass pollen SIT in hay fever patients by injecting the allergen directly into subcutaneous lymph nodes. In a monocentric randomized trial safety and efficacy of intralymphatic immunotherapy (ILIT) with 3 low dose grass pollen extract injections over 2 months are compared to subcutaneous immunotherapy (SCIT) using 54 injections over 3 years. Trial with immunodulatory product / biological

Official Title
-----------------
A Randomized Study to Evaluate a Novel Method of Specific Allergen Immunotherapy in Grass and/or Tree Pollen Allergic Subjects by Intralymphatic Allergen Administration

Conditions
-----------------
Rhinoconjunctivitis Due to Grass Pollen Allergy

Intervention / Treatment
-----------------
* Biological: Allergen specific immunotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Written informed consent History of allergic rhino-conjunctivitis in spring and summer Age 18 years to 65 years Positive skin prick test to grass pollen Exclusion criteria: Blood donation within previous 30 days Surgery within the previous 30 days Use of investigational drugs within previous 90 days Pregnancy or nursing Mastocytosis Significant cardiovascular disease Hypertension Active infectious disease Significant hepatic disease Significant renal disease Significant hematological disorder Significant pulmonary disease Moderate or severe asthma Autoimmune disease History of malignancy. Contraindicated medications were immunosuppressive agents, beta-blockers, ACE-inhibitors, and tricyclic antidepressants.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: Allergen specific immunotherapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety efficacy and toxicity |  | 3 years |
Safety and Efficacy Analysis of FRED® Embolic Device in Aneurysm Treatment

Study Overview
=================
Brief Summary
-----------------
A prospective, multicenter, observational evaluation of the safety and efficacy of the FRED® device in the treatment of intracranial aneurysms.

Official Title
-----------------
Safety and Efficacy Analysis of FRED® Embolic Device in Aneurysm Treatment

Conditions
-----------------
Intracranial Aneurysms

Intervention / Treatment
-----------------
* Device: FRED®


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient is aged ≥18 years Patient has an unruptured or recanalized intracranial aneurysm : for which an endovascular treatment has been determined appropriate that can not be treated by standard techniques (coiling with or without remodeling) and for which the FRED® Flow Diverter has been determined an appropriate treatment Patient or patient's legally authorized representative has been informed about the confidentiality of the study and agrees to the collection of his/her personal data Patient presents with an mRS score between 0 and 2 Patients who have already been treated with a stent or a flow diverter for another aneurysm may be included if: the previous treatment was more than three months prior to enrollment in this study the aneurysm to be treated for this study is a new aneurysm located on a different parent vessel unless the stent already in place is implanted on the proximal carotid artery. Exclusion Criteria: Patient has a known allergy to antiplatelet therapy, heparin and/or contrast medium Patient has contraindication to antiplatelet therapy and/or heparin Patient is pregnant and/or breastfeeding Patient may not benefit from imaging and clinical monitoring Patient has a medical or surgical co-morbidities limiting his/her life expectancy to less than 1 year Patient will be treated with a flow diverter other than FRED® Patient had an intracranial hemorrhage within the 30 days preceding treatment Patient has an aneurysm(s) with one or more of the following characteristics: associated with an arteriovenous malformation dissecting or blister-like multiple (unless only one aneurysm requires treatment) located in the posterior circulation treated with a stent or a flow diverter on the same parent vessel (excluding proximal carotid artery) or in the 3 months prior to inclusion Patient has stenosis of the aneurysm parent artery.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| FRED®<br> | Device: FRED®<br>* Flow Re-Direction Endoluminal Device<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Aneurysm occlusion without ˃ 50% parent artery stenosis |  | 6 months | 
| Morbidity rate |  | 6 months | 
| Mortality rate |  | 6 months |
Compassion Fatigue in ED Providers

Study Overview
=================
Brief Summary
-----------------
This study will assess compassion fatigue among healthcare providers in a single emergency department (ED) using the Professional Quality of Life (ProQoL) scale.

Official Title
-----------------
Compassion Fatigue Among Emergency Department Healthcare Providers

Conditions
-----------------
Compassion Fatigue

Intervention / Treatment
-----------------
* Behavioral: Professional Quality of Life (ProQoL) scale


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Currently employed as a health care provider in the emergency department. All eligible individuals will be 18 years and older. Exclusion Criteria: Individuals that are not currently employed in the emergency department

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Emergency Department Healthcare Providers<br>This study will assess compassion fatigue among healthcare providers in a single emergency department (ED) using the Professional Quality of Life (ProQoL) scale. | Behavioral: Professional Quality of Life (ProQoL) scale<br>* COMPASSION SATISFACTION AND COMPASSION FATIGUE (PROQOL) measures how compassion for those who are cared for can affect providers in positive and negative ways. Questions about experiences, both positive and negative, as a provider reflecting the frequency experiences within the last 30 days. 1=Never 2=Rarely 3=Sometimes 4=Often 5=Very Often<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess Compassion Fatigue as precursory research | Professional Quality of Life Scale survey (PROQOL) assesses compassion satisfaction and compassion fatigue. 1=Never 2=Rarely 3=Sometimes 4=Often 5=Very Often | Baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Emergency Department
Effect of Metformin as add-on Therapy on Glycemic Control and Other Outcomes in Type 1 Diabetes

Study Overview
=================
Brief Summary
-----------------
Aim Evidence of a possible connection between gut microbiota and several physiological processes linked to type 1 diabetes is increasing. However, the effect of multistrain probiotics in people with type 1 diabetes remains unclear. This study investigated the effect of metformin as add-on therapy on glycemic control and other diabetes-related outcomes in people with type 1 diabetes.

Detailed Description
-----------------
Design An open-label, add-on, self-control clinical trial. Setting Diabetes clinic of a teaching hospital in Shenzhen China Participants A total of 20 participants with type 1 diabetes, aged 18-60 years, will be recruited and treated with metformin as add-on therapy with insulin for 12 weeks. Outcomes Primary outcomes were glycemic control related parameters, and secondary outcomes were anthropomorphic variables, lipid profile, blood pressure and high-sensitivity C-reactive protein. The gut microbiota profile will be analyzed before and after intervention .

Official Title
-----------------
Effect of Metformin as add-on Therapy on Glycemic Control and Other Diabetes-Related Outcomes in Type 1 Diabetic Patients:a Open-label,Self-control Study

Conditions
-----------------
Type 1 Diabetes Mellitus, Metformin

Intervention / Treatment
-----------------
* Drug: Metformin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: type 1 diabetes patients age 18-60years old 18 Kg/m2≤BMI≤30Kg/m2 ketonuria (-)； Exclusion Criteria: pregnancy lactation having other severe chronic illnesses taking other anti-diabetic drugs

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: metformin<br>patients take metformin 500mg twice or three times a day as add-on therapy to insulin for 3 months ,using self-control method. | Drug: Metformin<br>* take the metformin 500mg twice or three times a day<br>* Other names: metformin hydrochloride tablets;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of hemoglobin A1c in percentage | analyze the change of hemoglobin A1c before and after the treatment | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of weight in kilograms | analyze the change of weight in kilograms before and after the treatment | 3 months |